Loading…

Sex Hormone Receptor Expression in Craniopharyngiomas and Association with Tumor Aggressiveness Characteristics

Craniopharyngiomas (CPs) are rare tumors of the sellar and suprasellar regions of embryonic origin. The primary treatment for CPs is surgery but it is often unsuccessful. Although CPs are considered benign tumors, they display a relatively high recurrence rate that might compromise quality of life....

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2022-01, Vol.11 (1), p.281
Main Authors: Martínez-Ortega, Antonio, Flores-Martinez, Álvaro, Venegas-Moreno, Eva, Dios, Elena, Del Can, Diego, Rivas, Eloy, Kaen, Ariel, Cárdenas Ruiz-Valdepeñas, Eugenio, Fajardo, Elena, Roldán, Florinda, González-Rivera, Natividad, Oliva, Rosario, Fernández-Peña, José Ignacio, Soto-Moreno, Alfonso, Cano, David A
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Craniopharyngiomas (CPs) are rare tumors of the sellar and suprasellar regions of embryonic origin. The primary treatment for CPs is surgery but it is often unsuccessful. Although CPs are considered benign tumors, they display a relatively high recurrence rate that might compromise quality of life. Previous studies have reported that CPs express sex hormone receptors, including estrogen and progesterone receptors. Here, we systematically analyzed estrogen receptor α (ERα) and progesterone receptor (PR) expression by immunohistochemistry in a well-characterized series of patients with CP ( = 41) and analyzed their potential association with tumor aggressiveness features. A substantial proportion of CPs displayed a marked expression of PR. However, most CPs expressed low levels of ERα. No major association between PR and ERα expression and clinical aggressiveness features was observed in CPs. Additionally, in our series, β-catenin accumulation was not related to tumor recurrence.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm11010281